Refractory B-Cell Non-Hodgkin Lymphoma

Known as: B-Cell Lymphoma Refractory, Refractory B-Cell Lymphoma, Refractory B-Cell Non-Hodgkin's Lymphoma 
B-cell non-Hodgkin lymphoma that is resistant to treatment.
National Institutes of Health

Topic mentions per year

Topic mentions per year

1991-2017
0246819912017

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2014
2014
Lymphoma cells are subject to higher levels of oxidative stress compared with their normal counterparts and may be vulnerable to… (More)
  • table 1
  • table 2
  • figure 1
  • table 3
  • table 4
Is this relevant?
2013
2013
As CD20 has become an established target for treating B-cell malignancies, there is interest in developing anti-CD20 antibodies… (More)
  • table 1
  • table 2
  • table 3
  • figure 1
  • figure 2
Is this relevant?
2012
2012
Inotuzumab ozogamicin (CMC-544), a humanized anti-CD22 antibody conjugated to the potent cytotoxic antibiotic calicheamicin… (More)
Is this relevant?
Highly Cited
2009
Highly Cited
2009
PURPOSE The growth of non-Hodgkin lymphomas can be influenced by tumor-immune system interactions. Cytotoxic T-lymphocyte antigen… (More)
  • table 1
  • table 2
  • table 3
  • table 4
  • figure 1
Is this relevant?
2009
2009
PURPOSE To determine the maximum-tolerated radiation-absorbed dose (RAD) to critical organs delivered by yttrium-90 ((90)Y… (More)
  • table 1
  • figure 1
  • table 2
  • figure 2
  • table 3
Is this relevant?
2008
2008
PURPOSE B-lymphocyte stimulator and a proliferation-inducing ligand regulate B-cell homeostasis and immunoglobulin production and… (More)
Is this relevant?
2007
2007
Denileukin diftitox plus rituximab was evaluated in relapsed/refractory B-cell non-Hodgkin lymphoma patients. Of the 38 evaluable… (More)
Is this relevant?
Highly Cited
2005
Highly Cited
2005
PURPOSE Evaluate efficacy and toxicity of bortezomib in patients with relapsed or refractory B-cell non-Hodgkin's lymphoma… (More)
Is this relevant?
2004
2004
PURPOSE Denileukin diftitox is a fusion protein combining diphtheria toxin and interleukin-2 (IL-2) that targets tumor cells… (More)
Is this relevant?
Highly Cited
2000
Highly Cited
2000
CD20-targeted radioimmunotherapy is a promising new treatment for B-cell non-Hodgkin lymphoma (NHL). We now provide updated and… (More)
  • table 1
  • figure 2
  • figure 1
  • table 2
  • figure 3
Is this relevant?